Clozapine Therapy for Parkinson’s Disease Psychosis: A 21-Year Service Analysis
Objective: To review the demographic aspects, safety, and efficacy of Clozapine treatment for Parkinson’s Disease Psychosis (PDP) in a large patient cohort. Background: The impact…Keeping patients out of care facilities— clozapine rescues Parkinson’s patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.
Objective: We describe a single-center cohort of Parkinson patients in crisis with troublesome psychosis unresponsive to quetiapine and pimavanserin, who were rescued by treatment with…Malignant catatonia secondary to clozapine withdrawal: A case report
Objective: To report a patient with malignant catatonia from abrupt clozapine discontinuation. Background: Clozapine blocks 5HT2A/5HT2C serotonin and dopamine receptors. Cholinergic and serotoninergic rebounds have…Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice
Objective: To examine if actual clinical practice of antipsychotic use in Parkinson's Disease patients are consistent with published evidence-based reviews of treatment recommendations and discuss…Neuroleptic medication is associated with a worse health status in the years prior to treatment, but have the potential for normalization
Objective: To determine the interval between impact on health-related quality of life (HRQL) and initiation of treatment with neuroleptics in patients with Parkinson's disease (PD)…Systematic literature review of quetiapine for hallucinosis / psychosis in Parkinson’s disease (PD)
Objective: To conduct a systematic review to evaluate the efficacy, safety, and dosing range of quetiapine for the treatment for hallucinosis / psychosis in patients…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.